Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?
The use of GnRH antagonist rather than agonist cotreatment during ovarian hyperstimulation for IVF is not widely accepted. Possible benefits, current shortcomings, and avenues for future development are discussed.